Literature DB >> 24638008

In vivo imatinib sensitivity in a patient with GI stromal tumor bearing a PDGFRA deletion DIM842-844.

Paul T Fanta1, Jason K Sicklick2, Bryan L Betz3, Michael R Peterson2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24638008      PMCID： PMC4884274          DOI： 10.1200/JCO.2013.50.0082

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

Review 1.  PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.

Authors:  Christopher L Corless; Arin Schroeder; Diana Griffith; Ajia Town; Laura McGreevey; Patina Harrell; Sharon Shiraga; Troy Bainbridge; Jason Morich; Michael C Heinrich
Journal:  J Clin Oncol       Date:  2005-05-31       Impact factor: 44.544

2.  Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.

Authors:  Philippe A Cassier; Elena Fumagalli; Piotr Rutkowski; Patrick Schöffski; Martine Van Glabbeke; Maria Debiec-Rychter; Jean-François Emile; Florence Duffaud; Javier Martin-Broto; Bruno Landi; Antoine Adenis; François Bertucci; Emmanuelle Bompas; Olivier Bouché; Serge Leyvraz; Ian Judson; Jaap Verweij; Paolo Casali; Jean-Yves Blay; Peter Hohenberger
Journal:  Clin Cancer Res       Date:  2012-06-20       Impact factor: 12.531

3.  A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential.

Authors:  Jerzy Lasota; Agnieszka Dansonka-Mieszkowska; Leslie H Sobin; Markku Miettinen
Journal:  Lab Invest       Date:  2004-07       Impact factor: 5.662

4.  Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.

Authors:  Barbara Dewaele; Bartosz Wasag; Jan Cools; Raf Sciot; Hans Prenen; Peter Vandenberghe; Agnieszka Wozniak; Patrick Schöffski; Peter Marynen; Maria Debiec-Rychter
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

5.  Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.

Authors:  Maria Debiec-Rychter; Bartosz Wasag; Michel Stul; Ivo De Wever; Allan Van Oosterom; Anne Hagemeijer; Raf Sciot
Journal:  J Pathol       Date:  2004-04       Impact factor: 7.996

6.  Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

Authors:  Burton L Eisenberg; Jonathan Harris; Charles D Blanke; George D Demetri; Michael C Heinrich; James C Watson; John P Hoffman; Scott Okuno; John M Kane; Margaret von Mehren
Journal:  J Surg Oncol       Date:  2009-01-01       Impact factor: 3.454

7.  Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site.

Authors:  Bartosz Wasag; Maria Debiec-Rychter; Patrick Pauwels; Michel Stul; Hilde Vranckx; Allan Van Oosterom; Anne Hagemeijer; Raf Sciot
Journal:  Mod Pathol       Date:  2004-08       Impact factor: 7.842
  7 in total
  5 in total

1.  Diagnosis and Treatment Monitoring of a Patient with Gastrointestinal Stromal Tumor by Next-Generation Sequencing and Droplet Digital Polymerase Chain Reaction Assay of a PDGFRA Mutation in Plasma-Derived Cell-Free Tumor DNA.

Authors:  Pieter A Boonstra; Arja Ter Elst; Marco Tibbesma; Jourik A Gietema; Ed Schuuring; Anna K L Reyners
Journal:  Oncologist       Date:  2019-01-22

2.  Surgical Management of Adolescents and Young Adults With Gastrointestinal Stromal Tumors: A US Population-Based Analysis.

Authors:  Katherine E Fero; Taylor M Coe; Paul T Fanta; Chih-Min Tang; James D Murphy; Jason K Sicklick
Journal:  JAMA Surg       Date:  2017-05-01       Impact factor: 14.766

3.  Imatinib therapy in acute myeloid leukemia with DEK-NUP214 and FIP1L1-PDGFRA rearrangement: A case report.

Authors:  Yanping Yang; Hai Lin; Zhonghua Du; Ruiping Hu; Yang Tang; Xinyue Liang; Jingnan Sun; Yehui Tan
Journal:  Oncol Lett       Date:  2020-03-10       Impact factor: 2.967

4.  FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.

Authors:  Eileen Shi; Juliann Chmielecki; Chih-Min Tang; Kai Wang; Michael C Heinrich; Guhyun Kang; Christopher L Corless; David Hong; Katherine E Fero; James D Murphy; Paul T Fanta; Siraj M Ali; Martina De Siena; Adam M Burgoyne; Sujana Movva; Lisa Madlensky; Gregory M Heestand; Jonathan C Trent; Razelle Kurzrock; Deborah Morosini; Jeffrey S Ross; Olivier Harismendy; Jason K Sicklick
Journal:  J Transl Med       Date:  2016-12-14       Impact factor: 5.531

5.  Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs).

Authors:  Michael C Heinrich; Janice Patterson; Jonathan A Fletcher; Sebastian Bauer; Carol Beadling; Yuexiang Wang; Maria Debiec-Rychter; Barbara Dewaele; Christopher L Corless; Anette Duensing; Chandrajit P Raut; Brian Rubin; Tamas Ordog; Matt van de Rijn; Jerry Call; Thomas Mühlenberg
Journal:  Clin Sarcoma Res       Date:  2019-03-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.